Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Isarna Therapeutics GmbH
DescriptionAntisense oligonucleotide targeting transforming growth factor (TGF) beta 2 (TGFB2)
Molecular Target Transforming growth factor (TGF) beta 2 (TGFB2)
Mechanism of Action 
Therapeutic ModalityNucleic acid
Latest Stage of DevelopmentPhase I
Standard IndicationGlaucoma
Indication DetailsPrevent scarring following glaucoma filtration surgery; Treat open-angle glaucoma
Regulatory Designation U.S. - Orphan Drug (Prevent scarring following glaucoma filtration surgery);
EU - Orphan Drug (Treat open-angle glaucoma)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today